Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

GF003AF

Sigma-Aldrich

Fibroblast Growth Factor basic, human

Animal free, >95% (SDS-PAGE), recombinant, expressed in E. coli, suitable for cell culture

Synonyme(s) :

FGF-2, bFGF, basic-FGF, Heparin-Binding Growth Factor 2, Prostatropin

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12352202
eCl@ss :
32160405
Nomenclature NACRES :
NA.75

product name

Fibroblast Growth Factor basic, human recombinant, animal-free, The Fibroblast Growth Factor-basic (or bFGF protein) is a heparin binding growth factor which stimulates the proliferation of a wide variety of cells including mesenchymal, neuroectodermal & endothelial cells.

Source biologique

human

Niveau de qualité

Pureté

>95% (SDS-PAGE)

Fabricant/nom de marque

Chemicon®

Technique(s)

cell culture | stem cell: suitable

Impuretés

<0.1 EU/μg Endotoxin (of bFGF)

Entrée

sample type epithelial cells
sample type mesenchymal stem cell(s)
sample type: human embryonic stem cell(s)
sample type neural stem cell(s)
sample type pancreatic stem cell(s)

Numéro d'accès NCBI

Numéro d'accès UniProt

Description générale

Fibroblast Growth Factor-basic (bFGF) is a heparin binding growth factor which stimulates the proliferation of a wide variety of cells including mesenchymal, neuroectodermal and endothelial cells. bFGF also exerts a potent angiogenic activity in vivo. Human bFGF is a 17.2 kDa protein containing 155 amino acid residues. Xu, et al. demonstrated that bFGF synergizes with the BMP antagonist noggin to sustain undifferentiated proliferation of human embryonic stem (hES) cells under feeder-free conditions. GF003AF was developed without animal-based ingredients and can be used for the culture of hES cells in a feeder-free, animal-free culture system.
Product Source: expressed in E. coli

Application

For most in vitro applications, bFGF exerts its biological activity in the concentration range of 0.1 to 10.0 ng/mL. Responding cells are (partial list): Endothelial, mesenchymal cells. Human ES cells require concentrations in the range of 4 to 100 ng/ml, depending on the method of culture

Forme physique

Lyophilized from a solution of 5mM Tris, pH 7.6 with 150 mM NaCl.

Stockage et stabilité

Maintain the lyophilized material at -20°C until expiration date as stated on the label.

General applications:
After a quick spin, reconstitute in 0.1M phosphate buffer, pH 6.8, to a concentration of 0.1-1.0 mg/mL. Reconstituted bFGF should be stored in working aliquots at -20°C for up to six months. Multiple freeze/thaw cycles will result in significant loss of activity.

For Human ES cell culture:
After a quick spin, reconstitute to 10 μg/mL in a filtered solution of 0.5% BSA, 1 mM DTT, and 10% glycerol in Dulbecco′s PBS. Aliquot and store at -20°C for up to six months. This solution can then thawed and diluted to 4 ng/mL for the culture of human ES cells with a feeder layer, or to 8 ng/mL to supplement mouse embryonic fibroblast-conditioned medium (for feeder-free human ES cell culture).

Remarque sur l'analyse

Specific Activity: Human FGF-b is fully biologically active when compared to standards. The ED50 was determined by the dose-dependent stimulation of thymidine uptake by NIH3T3 cells expressing FGF receptors.

Informations légales

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Leidan Huang et al.
Acta biomaterialia, 129, 73-83 (2021-05-09)
Vascularization is a critical step following implantation of an engineered tissue construct in order to maintain its viability. The ability to spatially pattern or direct vascularization could be therapeutically beneficial for anastomosis and vessel in-growth. However, acellular and cell-based strategies
Mitra Aliabouzar et al.
Ultrasonics sonochemistry, 66, 105109-105109 (2020-04-06)
An ultrasound standing wave field (SWF) has been utilized in many biomedical applications. Here, we demonstrate how a SWF can enhance drug release using acoustic droplet vaporization (ADV) in an acoustically-responsive scaffold (ARS). ARSs are composite fibrin hydrogels containing payload-carrying
Hai Jin et al.
Journal of controlled release : official journal of the Controlled Release Society, 338, 773-783 (2021-09-17)
Pro-angiogenic growth factors have been studied as potential therapeutics for cardiovascular diseases like critical limb ischemia (CLI). However, the translation of these factors has remained a challenge, in part, due to problems associated with safe and effective delivery. Here, we
Sarah E Elzinga et al.
Frontiers in immunology, 13, 1012594-1012594 (2022-10-18)
Obesity, prediabetes, and diabetes are growing in prevalence worldwide. These metabolic disorders are associated with neurodegenerative diseases, particularly Alzheimer's disease and Alzheimer's disease related dementias. Innate inflammatory signaling plays a critical role in this association, potentially via the early activation
Leiming Xia et al.
Cancer cell international, 21(1), 337-337 (2021-07-05)
Additional epidermal growth factor receptor (EGFR) mutations confer the drug resistance to generations of EGFR targeted tyrosine kinase inhibitor (EGFR-TKI), posing a major challenge to developing effective treatment of lung adenocarcinoma (LUAD). The strategy of combining EGFR-TKI with other synergistic

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique